Cite

HARVARD Citation

    Turner, R. et al. (n.d.). Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer's disease: A phase 2, double‐blind, randomized, placebo‐controlled trial. Alzheimer's & dementia. p. n/a. [Online]. 
  
Back to record